Gilead’s Timely Spike In Lobby Spending Leads To Speculation On Pricing Strategy

As pharmaceutical companies scrambled to push their COVID-19 treatments toward Phase III trials, many spent more on first-quarter lobbying than ever before. The nonprofit Center for Responsive Politics, who compiles lobbying and campaign finance data, noted that Gilead, AbbVie and Regeneron were among those who dramatically increased their Q1’20 lobby spending...